“ Lupin ' s biosimilars are developed in compliance with international regulatory standards, including those set by the US FDA, EMA, WHO, PMDA, and Indian regulatory bodies.”
in biomanufacturing processes. They allow for rapid setup and changeover between production runs, making it easier to adapt to changing market demands and scale up or down as needed.
Despite these advantages, SUTs also face challenges such as material compatibility, leachables and extractables, and supply chain reliability. Addressing these challenges is essential for the broader adoption and success of SUTs in biomanufacturing. Many modern facilities use a hybrid approach, combining the benefits of both technologies to optimize their operations.
What is the potential of Microfluidics and 3D Cell Culture to revolutionize drug discovery and development?
Microfluidic platforms enable highthroughput screening of drug candidates by processing small volumes of samples quickly and
“ Lupin ' s biosimilars are developed in compliance with international regulatory standards, including those set by the US FDA, EMA, WHO, PMDA, and Indian regulatory bodies.”
efficiently. This accelerates the identification of promising compounds and reduces costs associated with traditional screening methods. Microfluidics allows for precise control over biochemical reactions and processes, facilitating the miniaturization and automation of laboratory techniques.
3D cell culture technologies create environments that closely resemble invivo conditions, providing more accurate models for drug testing. 3D cultures, including spheroids, organoids, and organs-on-chips, offer better insights into drug efficacy and toxicity. These cultures are valuable for disease modeling, allowing researchers to study disease progression and drug effects in a controlled setting. By providing more accurate human-like models, 3D cell cultures can reduce the reliance on animal testing. This not only addresses ethical concerns but also improves the relevance of preclinical testing to human biology.
BioTech
BIOVOICENEWS. COM 29